Amphastar Pharmaceuticals... (AMPH)

Amphastar Pharmaceuticals is rated a buy due to strong Q2 earnings, value metrics, and promising pipeline developments. AMPH beat revenue and EPS estimates in Q2, with BAQSIMI sales up 21% YoY, offset...

Investors need to pay close attention to AMPH stock based on the movements in the options market lately.

RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be par...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.'s AMPH Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, an...

Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chr...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Commu...

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street...

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.94 per share a year ago.